Results 301 to 310 of about 379,925 (396)

Relationship between amino acid transporter activity and radioactive iodine therapy efficacy in differentiated thyroid cancer. [PDF]

Oncol Rep
Kotani A, Tatara Y, Sakamoto R, Wojcik A, Mariya Y, Monzen S.   +5 more
europepmc   +1 more source

The 2025 ATA guidelines for differentiated thyroid Cancer - Ten years of professional debate and measured progress

Petra Petranović Ovčariček, Frederik Anton Verburg, Bart de Keizer, Alfredo Campennì, M. Tuncel, Michael C. Kreißl, Désirée Deandreis, Luca Giovanella   +7 more
openalex   +1 more source

Safety of Baricitinib for the Treatment of Atopic Dermatitis in Adults Over a Median of 1.6 and up to 4.6 Years Treatment: Final Integrated Analysis of Eight Clinical Trials

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Baricitinib is a selective Janus kinase (JAK)1/JAK2 inhibitor approved in more than 70 countries for the treatment of moderate‐to‐severe atopic dermatitis (AD) in adults, and in over 30 countries for adolescents and children from age 2 years with moderate‐to‐severe AD, who are candidates for systemic therapy.
Antonio Costanzo, Antonio Torrelo, Eric L. Simpson, Marjolein De Bruin‐Weller, Diamant Thaçi, Norito Katoh, Silvia Sabatino, Andrew Buchanan, Kasia Morawska, Samuel Ogwu, Karen Denning, Jonathan I. Silverberg   +11 more
wiley   +1 more source

[¹⁸F]Tetrafluoroborate PET/CT for detecting differentiated thyroid cancer: phase-II study protocol. [PDF]

Future Oncol
Coerts HI, van Ginhoven TM, Visser WE, Windhorst AD, Vriens MR, van Treijen MJC, de Keizer B, Verburg FA.   +7 more
europepmc   +1 more source

Successful Treatment of Paediatric Necrobiosis Lipoidica With Baricitinib

JEADV Clinical Practice, EarlyView.
ABSTRACT Necrobiosis lipoidica (NL) is a rare, chronic granulomatous condition that typically presents as sharply demarcated plaques with telangiectasia and atrophic centres. Paediatric cases are uncommon, and treatment options often fail to address refractory cases.
P. Simões Farinha, M. J. Paiva‐Lopes
wiley   +1 more source

Neoadjuvant lenvatinib in a patient with invasive poorly differentiated thyroid cancer. [PDF]

Ecancermedicalscience
Zund S, Califano I, Carrizo F, Quildrian S.   +3 more
europepmc   +1 more source

Concurrent Psoriasis and Dermatomyositis: Retrospective Analysis and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis (PsO) and dermatomyositis (DM) are both autoimmune‐mediated, inflammatory conditions. The concurrence of PsO and DM is rare, and literature on their relationship remains limited. Additionally, cutaneous DM can be challenging to clinically diagnosis, often presenting with psoriasiform clinical features.
Emily R. Gordon, Karishma S. Shah, Sidharth Chand, Bonnie Lee, Janellen Smith, Michelle S. Min   +5 more
wiley   +1 more source

PET imaging of differentiated thyroid cancer with thyrotropin-alfa. [PDF]

Sci Rep
Gimblet GR, Reddy P, Holland MM, Houson HA, Whitt J, Copland JA, Kenderian SS, Jaskula-Sztul R, Lapi SE.   +8 more
europepmc   +1 more source

TET3‐Mediated m5C Modification of CCAT2 Accelerates Cardiac Microvascular Endothelial Cell Damage in Acute Coronary Syndrome

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Acute coronary syndrome (ACS) is a clinical syndrome involving myocardial ischemia. This study aimed to elucidate the mechanism of TET3 in ACS‐induced CMEC damage, thereby identifying a new target for ACS treatment. The expression of TET3 in ACS patients and healthy subjects was analyzed.
Jun‐Cheng Liu, Wen‐Juan Wang, Ting‐Ting Zhang, Qi‐Chong Yang, Haliminai Dilimulati, Song‐Tao An   +5 more
wiley   +1 more source

Regarding: 'impact of parathyroid gland classification on hypoparathyroidism following total thyroidectomy with central neck dissection for differentiated thyroid cancer'. [PDF]

Ann Med
Zhou Y, Zhang D, Cai M.
europepmc   +1 more source